Skip to content

Improving care of attention deficit hyperactivity disorder (ADHD) in people who use drugs

Managing substance use disorder (SUD) in the presence of Attention Deficit Hyperactivity Disorder (ADHD): does active management of ADHD improve outcomes in terms of reduced drug use and improved quality of life?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12624000269538
Enrollment
78
Registered
2024-03-18
Start date
2024-01-03
Completion date
2025-09-30
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

ADHD is a common neurodevelopmental disorder defined by the persistence of dysregulated attention, activity and impulsivity. The incidence of ADHD in childhood is 6-7%. Some symptoms improve in adolescence, but 2–4% of adults continue to meet the diagnostic criteria. ADHD is recognised in 3 to 4 times as many people seeking help for substance use disorder (SUD) as in the general population. Adults with ADHD who use drugs are often misdiagnosed and cannot access effective, targeted, multidisciplinary care. Individual specialists and specialist services will not treat ADHD in the presence of SUD. This project aims to demonstrate that recognition of ADHD and active management significantly improve quality of life and reduce substance use in people seeking help for SUD.

Interventions

The subjects will be divided randomly on enrolment into tow groups. Group A will be immediately be provided with additional services including case management, counselling, access to ADHD coaching, and a mental health review with a psychiatrist. A research nurse will provide case management. All contacts and reviews (including telehealth review) will be recorded. Group B will be offered all the additional services after 6 months of treatment as usual. Treatment as usual consists of assessment

The subjects will be divided randomly on enrolment into tow groups. Group A will be immediately be provided with additional services including case management, counselling, access to ADHD coaching, and a mental health review with a psychiatrist. A research nurse will provide case management. All contacts and reviews (including telehealth review) will be recorded. Group B will be offered all the additional services after 6 months of treatment as usual. Treatment as usual consists of assessment by an addiction medicine specialist, psychiatric registrar or psychiatrist who prescribes medication, provides psychoeducation and reviews the patients as required. The additional services include: (a) case management by a nurse or alcohol and other drug case worker includes monitoring adherence and issuing reminders to ensure partiipation (b) access to coaching by a qualified ADHD coach (typically 10 weekly one hour sessions) (c) formal review of comorbid mental health issues by an independent psychiatrist (d) regular review (at least monthly) by the research nurse or an addiction medicine or addiction psychiatry consultant

Sponsors

Alcohol and Drug Research Innovation Agenda (ADRIA)
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Aged 18 year or over Score >= 14 on ASRS part A Have the diagnosis confirmed on interview (DIVA) Live within the Goulburn Valley Health catchment area

Exclusion criteria

Have a history of o Severe neurological disorders including stroke o Symptomatic cardiovascular disease o Hyperthyroidism o Moderate to severe hypertension o Glaucoma o Pheochromocytoma o Have a current acute psychotic illness o using mono-amine oxidase inhibitors o Are pregnant or breastfeeding at recruitment

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026